Ask AI

Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment

Gain a deeper understanding of the mechanisms of action and rationale for targeting TIGIT and TROP-2 in lung cancer based on recent clinical data and novel targeted therapies to increase clinical trial enrollment and enhance patient outcomes through a certified on-demand webcast, expert-authored ClinicalThought commentary, and accompanying downloadable slides.

Share

Program Content

Activities

Targeting TROP2 and TIGIT in lung cancer
Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 28, 2025

Activities

TROP2 and TIGIT Transforming Lung Cancer Treatment
Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment
Video
Congratulations: You achieved a completion on 04/09/2022

Released: September 04, 2025

Expires: March 03, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.